公开(公告)号：US10590174B2

公开(公告)日：2020-03-17

申请号：US16311913

申请日：2017-07-07

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE LA REUNION SAINT DENIS ,  INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Inventor： Gilles Gadea ,  Michael Girardot ,  Philippe Despres

IPC: C07K7/00 ,  C12N15/11 ,  A61K39/00 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.

公开(公告)号：US20190255125A1

公开(公告)日：2019-08-22

申请号：US16307689

申请日：2017-06-22

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite de la Reunion Saint Denis ,  Institut de Recherche pour le Developpement (IRD) ,  Centre National de la Recherche Scientifique (CNRS)

Inventor： Philippe DESPRES ,  Gilles GADEA ,  Patrick MAVINGUI ,  Wildriss VIRANAICKEN

IPC: A61K35/76 ,  A61P31/14

Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.

公开(公告)号：US20190177373A1

公开(公告)日：2019-06-13

申请号：US16311913

申请日：2017-07-07

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE LA REUNION SAINT DENIS ,  INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS

Inventor： Gilles GADEA ,  Michael GIRARDOT ,  Philippe DESPRES

IPC: C07K14/005 ,  C12N7/00

Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.

公开(公告)号：US10849943B2

公开(公告)日：2020-12-01

申请号：US16307689

申请日：2017-06-22

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite de la Reunion Saint Denis ,  Institut de Recherche pour le Developpement (IRD) ,  Centre National de la Recherche Scientifique (CNRS)

Inventor： Philippe Despres ,  Gilles Gadea ,  Patrick Mavingui ,  Wildriss Viranaicken

IPC: A61K39/00 ,  A61K39/12 ,  C12N7/00 ,  C07K14/005 ,  A61K39/39 ,  A61K35/76 ,  A61P31/14

Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.